To tackle one of the most urgent public health crises facing the world today – antimicrobial resistance (AMR) – universal health coverage (UHC) must be realized. It’s time to take action by ensuring that everyone has access to safe, effective, quality-assured medicines.
Evolution of Rifampin resistance in Escherichia coli and Mycobacterium smegmatis due to substandard drugs
Poor-quality medicines undermine the treatment of infectious diseases, such as tuberculosis, which require months of treatment with rifampin and other drugs.
In response to the growing AMR crisis, the UN Interagency Coordination Group on Antimicrobial Resistance (IACG) – which was created following the UN High-Level Meeting on AMR in 2016 – released its seminal report with recommendations on how to curb the spread of AMR.
Over the past few weeks since the World Health Assembly, we’ve seen quality integrated into seminal reports and WHO action plans on antimicrobial resistance (AMR), drug procurement and universal health coverage (UHC). We’re excited to see links made across these issues.
The prevalence of poor-quality antimicrobial medicines is widespread throughout Africa and Asia in lower income countries and lower middle-income countries.
Since our ancestors began trading several millennia ago, counterfeit and substandard medicines have been a recurring problem, with history punctuated by crises in the supply of anti-microbials, such as fake cinchona bark in the 1600s and fake quinine in the 1800s.
The selection and spread of antimalarial drug resistance pose enormous challenges to the health of people living in tropical countries.
Falciparum malaria kills, and it particularly kills the rural poor. Artemisinin derivatives, such as artesunate, are a vital component of Plasmodium falciparum malaria treatment and control in the face of globally increasing antimalarial drug resistance.